Effect of Pentoxifylline Plus Coenzyme Q10 Combination Therapy Compared to Coenzyme Q10 Alone on Sperm Motility in Sub-fertile Male With Asthenozoospermia

What this Trial Is About

Researchers are evaluating the effects of Pentoxifylline combined with Coenzyme Q10 compared to Coenzyme Q10 alone in treating asthenozoospermia, a condition characterized by reduced sperm motility in subfertile men. This clinical trial aims to determine whether the combination improves sperm motility and to assess the safety of the combined treatment. The study is randomized and involves adult men diagnosed with asthenozoospermia according to the 2021 WHO criteria. Participants will be randomly assigned to one of two groups: the experimental group receiving Pentoxifylline 400 mg plus Coenzyme Q10 100 mg twice daily, or the comparator group receiving Coenzyme Q10 100 mg twice daily. Both treatments last for three months. The trial includes baseline semen analysis with multiple samples collected to confirm eligibility and periodic assessments of sperm motility during the treatment period. During the study, participants will provide semen samples analyzed under standardized conditions using the Makler Counting Chamber to measure sperm motility at baseline and after 12 weeks of treatment. Researchers will collect detailed demographic and medical information, monitor adherence to the medication regimen, and evaluate safety. The primary outcome is progressive sperm motility measured before and after treatment, with secondary assessments of total sperm motility. Participants will visit the clinic for checkups and tests after treatment completion.

Effect of Pentoxifylline + CoQ10 vs CoQ10 Alone on Sperm Motility in Subfertile Men With Asthenozoospermia